{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01062568: Phase 3 Interventional Completed Development
(2010)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00024934: Phase 1 Interventional Completed IgA Deficiency
(2001)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00537420: Phase 2 Interventional Completed Obesity
(2007)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00088179: Phase 3 Interventional Completed Coronary Artery Disease
(2004)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00254397: Phase 2 Interventional Completed Melanoma
(2005)
Source URL:
Class:
PROTEIN
Disomotide is an oligopeptide in phase III clinical development for the treatment of melanoma. Vaccination with the disomotide peptide has resulted in very high levels of circulating T cells that were capable of recognizing and killing melanoma cancer cells in vitro. In a single-group, phase 2 study, patients with metastatic melanoma were immunized with the disomotide peptide vaccine in Montanide ISA-51 (incomplete Freund’s adjuvant), followed by high-dose interleukin-2, leading to objective clinical responses in 13 of 31 patients. Randomized study showed the clinical benefit of a vaccine in the treatment of patients with measurable metastatic melanoma. Patients receiving the disomotide with interleukin-2 were more than twice as likely to have a clinical response as those receiving interleukin-2 alone.
Status:
Investigational
Source:
INN:ismomultin alfa [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
USAN:CLIVATUZUMAB [USAN]
Source URL:
Class:
PROTEIN
